Research

Scientists trace severe COVID-19 to faulty genes and an autoimmune condition

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation.

In both groups, the upshot is basically the same: The patients lack type I interferon, a set of 17 proteins crucial for protecting cells and the body from viruses.

Johns Hopkins researchers publish COVID-19 'prediction model'

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today published a "prediction model" they say can help other hospitals care for COVID-19 patients - and make important decisions about planning and resource allocations.

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Baylor College of Medicine and the University of California San Diego. The resources are freely available through the Signaling Pathways Project (Baylor) and the Network Data Exchange (UCSD).

Researchers uncover early results about an existing tuberculosis vaccine that has been hypothesized to help against the coronavirus

While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widespread BCG vaccination appear to be weathering the pandemic better than their counterparts. This has led many researchers to suspect that BCG vaccine, which immunizes against tuberculosis, might offer protection against COVID-19.

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.

Progress toward antiviral treatments for COVID-19

COVID-19 is caused by a virus known as SARS-CoV-2, which is similar in structure to two other viruses that have caused recent outbreaks: SARS-CoV, which caused an outbreak of SARS in 2003, and MERS-CoV, the cause of a 2012 outbreak of Middle East Respiratory Syndrome.

Scientists trace severe COVID-19 to faulty genes and an autoimmune condition

Johns Hopkins researchers publish COVID-19 'prediction model'

Web resources bring new insight into COVID-19

Researchers uncover early results about an existing tuberculosis vaccine that has been hypothesized to help against the coronavirus

T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Progress toward antiviral treatments for COVID-19

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs